Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
183 hedge funds and large institutions have $2.08B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2017 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 61 increasing their positions, 62 reducing their positions, and 34 closing their positions.
14% more capital invested
Capital invested by funds: $1.83B → $2.08B (+$255M)
13% more call options, than puts
Call options by funds: $30.4M | Put options by funds: $27M
1% more funds holding
Funds holding: 181 → 183 (+2)
9% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 34
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
2% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
+$32.2M |
| 2 |
Renaissance Technologies
New York
|
+$16.4M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$15.9M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$14.5M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$34.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$19.1M |
| 3 |
Barclays
London,
United Kingdom
|
-$17M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$16.8M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$14.8M |
HZNP Hedge Fund Activity: Q4 2017 in Review
183 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q4 2017, worth a combined $2.08B — up 14% from $1.83B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new HZNP positions and 34 closed out — a net gain of 3 holders — while 61 added to existing stakes and 62 trimmed.
The largest buyer was Paulson & Co, adding an estimated $32.2M. The largest seller was Point72 Asset Management, cutting an estimated $34.2M.
- 183 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q4 2017, up from 181 in Q3 2017.
- Funds reported $2.08B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q4 2017, up 14% quarter-over-quarter.
- 37 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q4 2017 and 34 closed out, a net change of +3 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q4 2017 was Paulson & Co, an estimated $32.2M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q4 2017 was Point72 Asset Management, an estimated $34.2M sold.
Based on aggregated 13F filings for Q4 2017.